Using coronary artery calcium to guide cardiovascular risk reduction: insights from the CAUGHT-CAD trial

P Venkataraman,T Marwick,T Marwick,Q Huynh,Q Huynh

DOI: https://doi.org/10.1093/ehjci/ehaa946.2950

IF: 39.3

2020-11-01

European Heart Journal

Abstract:Abstract Introduction International guidelines now recognise the value of CT coronary artery calcium scoring (CAC) to guide statin prescribing decisions. However, evidence is conflicting on CAC's potential to reinforce clinical advice, promote adherence and facilitating positive health behavioural change. Purpose We sought to assess the impact of a CAC-guided statin treatment protocol on cardiovascular risk at 12 months. Methods The CAUGHT-CAD trial recruited 455 asymptomatic, statin-naïve individuals at intermediate risk CVD risk with a family history of premature coronary artery disease (CAD) and CAC scores between 1 and 400. Participants were randomised to visualisation of their CAC or remain blinded. Both groups were provided standard risk factor advice. We calculated the 10-year SCORE predicted risk based on participant's baseline and 12 month risk factor profile. Paired t test and regression analysis was used to assess change in predicted risk both within and between treatment group. Results CAC-visualisation and statin treatment resulted in a 0.45% absolute and 21% relative risk reduction in predicted SCORE risk at 1 year. The CAC exposure group demonstrated 2.78 mmHg reduction in systolic blood pressure compared to the blinded group (p<0.01); accounting for 25% of the predicted absolute risk reduction despite both groups reporting the same level of dietary and physical activity goals achieved. 9 blinded participants who were commenced on statins off-protocol showed attenuated reductions in lipids compared to the CAC exposed group (total cholesterol: m-0.5 vs. −1.5 mmol/L, p<0.01; LDL −0.6 mmol/L vs. −1.4 mmol/L, p<0.01) suggesting poorer adherence. Conclusion CAC visualisation can augment primary CVD prevention by improving systolic blood pressure and absolute reduction in lipids with statin treatment. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): NHMRC project grant

cardiac & cardiovascular systems